BioSpyder Launches miRNA Assay, Enhancing TempO-Seq Platform Capabilities

BioSpyder, a leader in advanced molecular biology technologies, announces the introduction of its whole “miRNome” TempO-Seq® miRNA assay.  A significant expansion of the TempO-Seq platform, researchers now have a comprehensive and efficient platform to measure the transcriptome of mRNA, miRnome, and genome of DNA variants.

The strength of the TempO-Seq whole miRnome assay lies in its ability to profile gene expression, miRNA, and carry out focused genotyping on the same sample lysate. The assay runs from bulk samples of cells, organoids or FFPE. To profile miRNA at the single cell level, the TempO-LINC protocol can be applied at a level of reproducibility which permits generation of precise dose-response data. In addition, the ability to quantitatively attenuate the signal from highly expressed miRNA to increase sensitivity to measure miRNA expressed at low levels, with the ability to accurately back-calculate the expression level of attenuated miRNA. The TempO-Seq miRNA assay is an instrument-free approach that can be run quickly and simply; researchers can now generate comprehensive miRNA profiles in as little as two days.

Joel McComb, Chief Executive Officer of BioSpyder, noted that “our miRNA assay fills a new void in the market, after BioSpyder successfully defended its comprehensive IP from HTG Molecular which subsequently declared bankruptcy.”

Bruce Seligmann, Chief Scientific Officer of BioSpyder, expressed excitement about the expansion of the TempO-Seq platform, stating, "We are thrilled to introduce TempO-Seq and TempO-LINC miRNA Whole miRnome assay kits and services, empowering researchers with a versatile tool for exploring both miRNA and mRNA expression patterns in bulk samples down to single-cells. This innovative assay holds great promise for applications in drug discovery, translational research, safety assessment, and diagnostics."

BioSpyder, known for its commitment to advancing molecular biology technologies, continues to play a pivotal role in various scientific fields, including toxicology, cancer biology, and environmental health. The company's TempO-Seq platform and related approaches are shaping the landscape of molecular research, facilitating breakthroughs in precision medicine and drug discovery.

For more information about the miRNA Whole Transcriptome Assay and BioSpyder's innovative technologies, please visit [website].

About BioSpyder: BioSpyder is a leading provider of advanced molecular biology technologies, dedicated to expanding scientific capabilities in toxicology, cancer biology, and environmental health. The company's TempO-Seq platform and related approaches continue to shape the landscape of molecular research, facilitating breakthroughs in drug discovery, translational research, and diagnostics.